Reducing Decoys Focuses Fighting Microglia

Overview

Journal Nat Aging

Specialty Geriatrics

Date 2023 Feb 16

PMID 36793992

Authors

Michael R Duggan

Keenan A Walker

Affiliations

Soon will be listed here.

Abstract

Genetic variation linked to lower levels of soluble ST2, a decoy cytokine receptor for IL-33, may protect against Alzheimer's disease in female ε4 carriers by increasing microglial plaque removal. This discovery advances our understanding of the immune system's role in Alzheimer's disease and underscores the importance of sex-specific disease processes.

References

Keren-Shaul H, Spinrad A, Weiner A, Matcovitch-Natan O, Dvir-Szternfeld R, Ulland T . A Unique Microglia Type Associated with Restricting Development of Alzheimer's Disease. Cell. 2017; 169(7):1276-1290.e17. DOI: 10.1016/j.cell.2017.05.018. View

Hayakawa H, Hayakawa M, Kume A, Tominaga S . Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J Biol Chem. 2007; 282(36):26369-80. DOI: 10.1074/jbc.M704916200. View

Duggan M, Parikh V . Microglia and modifiable life factors: Potential contributions to cognitive resilience in aging. Behav Brain Res. 2021; 405:113207. PMC: 8005490. DOI: 10.1016/j.bbr.2021.113207. View

Fu A, Hung K, Yuen M, Zhou X, Mak D, Chan I . IL-33 ameliorates Alzheimer's disease-like pathology and cognitive decline. Proc Natl Acad Sci U S A. 2016; 113(19):E2705-13. PMC: 4868478. DOI: 10.1073/pnas.1604032113. View

Ho J, Chen W, Chen M, Larson M, McCabe E, Cheng S . Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling. J Clin Invest. 2013; 123(10):4208-18. PMC: 3784527. DOI: 10.1172/JCI67119. View

Guillot-Sestier M, Araiz A, Mela V, Gaban A, ONeill E, Joshi L . Microglial metabolism is a pivotal factor in sexual dimorphism in Alzheimer's disease. Commun Biol. 2021; 4(1):711. PMC: 8192523. DOI: 10.1038/s42003-021-02259-y. View

Liu Y, Chen W, Lin Y, Lu P, Hsieh S, Cheng I . Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model. Mol Neurodegener. 2017; 12(1):30. PMC: 5402663. DOI: 10.1186/s13024-017-0173-0. View

Jiang Y, Zhou X, Wong H, Ouyang L, Ip F, Chau V . An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-ε4 in female patients with Alzheimer's disease. Nat Aging. 2023; 2(7):616-634. PMC: 10154240. DOI: 10.1038/s43587-022-00241-9. View

Serrano-Pozo A, Li Z, Noori A, Nguyen H, Mezlini A, Li L . Effect of alleles on the glial transcriptome in normal aging and Alzheimer's disease. Nat Aging. 2022; 1(10):919-931. PMC: 9531903. DOI: 10.1038/s43587-021-00123-6. View

10.

Sperling R, Donohue M, Raman R, Sun C, Yaari R, Holdridge K . Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol. 2020; 77(6):735-745. PMC: 7136861. DOI: 10.1001/jamaneurol.2020.0387. View

11.

Chakrabarty P, Li A, Ladd T, Strickland M, Koller E, Burgess J . TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer's disease. J Exp Med. 2018; 215(9):2247-2264. PMC: 6122970. DOI: 10.1084/jem.20180484. View